Clinical Trial Update: A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms [Phase 1]

View source ↗

Summary

Phase 1 study to assess pharmacologic equivalence between two orlistat dosage forms in overweight individuals; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overweight

Drugs mentioned

• Orlistat (orlistat)
• XENICAL (orlistat)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Overweight | Phase 1 | Status: COMPLETED